Shares of Dr.Reddy's Laboratories Ltd (NYSE:RDY) have been assigned an average rating of "Hold" from the six brokerages that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $53.00.
RDY has been the topic of a number of research analyst reports. Barclays lifted their target price on Dr.Reddy's Laboratories from $45.00 to $53.00 and gave the company an "equal weight" rating in a report on Thursday, July 30th. ValuEngine raised Dr.Reddy's Laboratories from a "sell" rating to a "hold" rating in a research report on Monday, August 3rd.
RDY stock opened at $60.49 on Wednesday. Dr.Reddy's Laboratories has a 52-week low of $33.33 and a 52-week high of $62.60. The stock's fifty day simple moving average is $59.89 and its 200-day simple moving average is $51.43. The company has a quick ratio of 1.17, a current ratio of 1.66 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $10.02 billion, a price-to-earnings ratio of 39.80 and a beta of 0.51.
Dr.Reddy's Laboratories (NYSE:RDY) last issued its earnings results on Wednesday, July 29th. The company reported $0.46 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.42 by $0.04. Dr.Reddy's Laboratories had a return on equity of 18.88% and a net margin of 10.26%. The firm had revenue of $585.00 million for the quarter. As a group, analysts anticipate that Dr.Reddy's Laboratories will post 1.93 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Thrivent Financial for Lutherans increased its position in shares of Dr.Reddy's Laboratories by 20.9% during the first quarter. Thrivent Financial for Lutherans now owns 34,498 shares of the company's stock worth $1,392,000 after acquiring an additional 5,953 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Dr.Reddy's Laboratories by 5.7% during the first quarter. Parametric Portfolio Associates LLC now owns 664,317 shares of the company's stock worth $26,792,000 after acquiring an additional 35,857 shares during the last quarter. Candriam Luxembourg S.C.A. bought a new stake in Dr.Reddy's Laboratories in the second quarter valued at about $742,000. First Trust Advisors LP increased its holdings in Dr.Reddy's Laboratories by 4.3% in the second quarter. First Trust Advisors LP now owns 128,180 shares of the company's stock valued at $6,795,000 after buying an additional 5,292 shares during the last quarter. Finally, Brinker Capital Inc. bought a new stake in Dr.Reddy's Laboratories in the second quarter valued at about $435,000. 12.79% of the stock is currently owned by institutional investors and hedge funds.
Dr.Reddy's Laboratories Company Profile
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.
Recommended Story: How is diluted EPS different from basic EPS?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Stocks That Could Provide a Year-End Rally
It’s rough in the markets right now. Underlying the volatility is uncertainty. The VIX Index (INDEXCBOE: VIX) otherwise known as the Fear Index is an unofficial, but an eerily accurate predictor of market sentiment. And the VIX is up 30% in the last month.
Is this uncertainty due to concerns over additional lockdown measures? Is it about the lack of additional coronavirus stimulus? Is the market reacting to a surge in jobless claims? Or is this just the somewhat normal volatility that comes in an election year that promises to be like none in American history.
The answer is all of the above and then some. But does that mean you should stay out of equities? I don’t think so. Where are you going to go? The Fed has promised interest rates are going nowhere fast. And that bit of news is weighing down the bond market.
So stocks it is. But although growth-seeking investors may be tempted to look at the tech sector to see what’s on sale today, I suggest taking a more targeted approach. Rather than looking at a single sector, try to look at solid performers in different sectors that may be ready to surge over the last three months.
The pandemic brought the entire market down. But once investors took a breath they found bargains. And if you had the courage to put your money to work in those stocks, you’ve been rewarded.
Times like these call for the same type of courage. And that’s why we’ve put together this special presentation with seven stocks that look ready to surprise investors with nice end-of-year gains.
View the "7 Stocks That Could Provide a Year-End Rally".